Second dose of Pfizer Inc’s Coronavirus (COVID-19) vaccine could be delayed in order to cover all priority groups as the first one is highly protective, two Canada-based researchers said in a letter published in the New England Journal of Medicine.<br /><br />The vaccine had an efficacy of 92.6% after the first dose, Danuta Skowronski and Gaston De Serres said, based on an analysis of the documents submitted by the drugmaker to the U.S. Food and Drug Administration (FDA).<br /><br />These findings were similar to the first-dose efficacy of 92.1% reported for Moderna Inc's mRNA-1273 vaccine, according to the letter here on Wednesday.<br /><br />In its response, Pfizer said alternative dosing regimens of the vaccine had not been evaluated yet and that the decision resided with the health authorities.<br /><br />This article was originally published by Reuters on February 18, 2021:<br />http://reut.rs/3k7LuF9<br /><br />FIND the model and photographer created this video on Pexels:<br />https://bit.ly/3aqnKYj<br /><br />SUBSCRIBE to our channel:<br />http://bit.ly/3pOwYUZ
